[January 03, 2013]

Ipsen's Corporate Agenda for 2013

Regulatory News:

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2013:

* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary

** Pending approval of the Board of directors (26^th February 2013) and of the General shareholders' meeting (31^st May 2013)

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport^®, endocrinology / Somatuline^®, uro-oncology / Decapeptyl^® and hemophilia. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

[ Back To Technology News's Homepage ]